Paid Clinical Trials Overland Park
Discover 422 paid clinical trials in Overland Park, Kansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
M3814 with RadiotherapyTesting the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04172532
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy Procedure
Biospecimen Collection
Computed Tomography
Hypofractionated Radiation Therapy
Magnetic Resonance Imaging
SBS-1000A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults
Sponsor:
Sparian Biosciences, Inc
Location:
Code:
NCT05721287
Conditions
Pain
Acute Pain
Eligibility Criteria
Sex: All
Age: 18 - 59
Healthy Volunteers: Accepted
Interventions
SBS-1000
Placebo
OviTex MeshVentral or Inguinal Hernia, Robotically Repaired With OviTex Mesh
Sponsor:
Tela Bio Inc
Location:
Code:
NCT04779918
Conditions
Hernia, Ventral
Hernia, Inguinal
Eligibility Criteria
Sex: All
Age: 21+
Healthy Volunteers: Accepted
Interventions
OviTex Reinforced Tissue Matrix
PF-08052666A Study of SGN-MesoC2 in Advanced Solid Tumors
Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Location:
Code:
NCT06466187
Conditions
Carcinoma, Non-Small-Cell Lung
Ovarian Neoplasms
Pancreatic Adenocarcinoma
Colorectal Neoplasms
Mesothelioma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
PF-08052666
Cardiac MonitorsComparative Analysis in Detection of Atrial Arrhythmia and ECG Quality in Three Different Insertable Cardiac Monitors
Sponsor:
Kansas City Heart Rhythm Research Foundation
Location:
Code:
NCT04471584
Conditions
Arrhythmias, Cardiac
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Insertion of ILR device
ZEN003694 with Cetuximab, EncorafenibTesting the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT06102902
Conditions
Metastatic Colorectal Adenocarcinoma
Recurrent Colorectal Adenocarcinoma
Refractory Colorectal Adenocarcinoma
Stage IV Colorectal Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BET Bromodomain Inhibitor ZEN-3694
Biopsy Procedure
Biospecimen Collection
Cetuximab
Computed Tomography
Laminar LAA EliminationA Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination
Sponsor:
Biosense Webster, Inc.
Location:
Code:
NCT06168942
Conditions
Non-valvular Atrial Fibrillation
Stroke
Systemic Embolism
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Experimental: Laminar Left Atrial Appendage Closure System
Active Comparator: WATCHMAN / Amulet
Observational StudyTriple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Sponsor:
University of Kansas Medical Center
Location:
Code:
NCT02302742
Conditions
Breast Cancer
Hereditary Breast and Ovarian Cancer
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Accepted
NewnormStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
Sponsor:
Octapharma
Location:
Code:
NCT04640142
Conditions
Primary Immune Deficiency
Eligibility Criteria
Sex: All
Age: 2 - 70+
Healthy Volunteers: Not accepted
Interventions
Newnorm